MICHAEL F CLARKE, M.D.
Radiology at Pasteur Dr, Palo Alto, CA
License number
California C52663
Category
Radiology
Type
Radiation Oncology
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 498-5710
Professional information
Prospective Identification And Characterization Of Breast Cancer Stem Cells
US Patent:
2009000, Jan 1, 2009
Filed:
Jan 9, 2007
Appl. No.:
11/651214
Inventors:
Michael F. Clarke - Palo Alto CA, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - La Jolla CA, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - La Jolla CA, US
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241721
Abstract:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
Prospective Identification And Characterization Of Breast Cancer Stem Cells
US Patent:
2011003, Feb 10, 2011
Filed:
Apr 12, 2010
Appl. No.:
12/758540
Inventors:
MICHAEL F. CLARKE - PALO ALTO CA, US
MAX S. WICHA - ANN ARBOR MI, US
MUHAMMAD AL-HAJJ - LA JOLLA CA, US
MAX S. WICHA - ANN ARBOR MI, US
MUHAMMAD AL-HAJJ - LA JOLLA CA, US
International Classification:
A61K 39/395, C12N 5/095, A61P 35/00
US Classification:
4241721, 435375
Abstract:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary glad of severely immunodeficient mice. These xenograft assays have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
Dr. Michael F Clarke, Stanford CA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
300 Pasteur Dr, Stanford 94305
(650) 498-5710 (Phone)
STANFORD UNIVERSITY INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE
265 Campus Dr STE G2021A, Stanford 94305
(650) 725-2495 (Phone), (650) 736-2961 (Fax)
(650) 498-5710 (Phone)
STANFORD UNIVERSITY INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE
265 Campus Dr STE G2021A, Stanford 94305
(650) 725-2495 (Phone), (650) 736-2961 (Fax)
Languages:
English
Hospitals:
300 Pasteur Dr, Stanford 94305
STANFORD UNIVERSITY INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE
265 Campus Dr STE G2021A, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
STANFORD UNIVERSITY INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE
265 Campus Dr STE G2021A, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
Indiana University / School of Medicine
Graduated: 1977
Indiana University / School of Medicine
Graduated: 1977
Isolation And Use Of Solid Tumor Stem Cells
US Patent:
8357491, Jan 22, 2013
Filed:
Dec 28, 2010
Appl. No.:
12/979991
Inventors:
Michael F. Clarke - Palo Alto CA, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Eagleville PA, US
Sean J. Morrison - Ann Arbor MI, US
Max S. Wicha - Ann Arbor MI, US
Muhammad Al-Hajj - Eagleville PA, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 612, 435 912
Abstract:
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
Compositions And Methods For Treating And Diagnosing Cancer
US Patent:
2011018, Jul 28, 2011
Filed:
Mar 31, 2011
Appl. No.:
13/077380
Inventors:
Michael F. Clarke - Palo Alto CA, US
Xinhao Wang - Fremont CA, US
John A. Lewicki - Los Gatos CA, US
Austin L. Gurney - San Francisco CA, US
Xinhao Wang - Fremont CA, US
John A. Lewicki - Los Gatos CA, US
Austin L. Gurney - San Francisco CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
ONCOMED PHARMACEUTICALS, INC. - Mountain View CA
ONCOMED PHARMACEUTICALS, INC. - Mountain View CA
International Classification:
C40B 30/04, C12Q 1/68
US Classification:
506 9, 435 61, 435 612
Abstract:
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.
Methods And Compositions For Treating Carcinoma Stem Cells
US Patent:
2011012, May 26, 2011
Filed:
Jan 30, 2009
Appl. No.:
12/865092
Inventors:
Maximilian Diehn - Stanford CA, US
Michael Clarke - Palo Alto CA, US
Irving L. Weissman - Stanford CA, US
Michael Clarke - Palo Alto CA, US
Irving L. Weissman - Stanford CA, US
International Classification:
C12Q 1/02
US Classification:
435 29
Abstract:
Cancer stem cells (CSCs) have been prospectively isolated or identified from primary tumor samples, and shown to possess the unique properties of self-renewal and differentiation, and can form unique histological microdomains useful in cancer diagnosis. Such cancer stem cells are shown herein to have the phenotype of containing decreased levels of reactive oxygen species (ROS) relative to non-tumorigenic (non-stem cell) cancer cells, as well as expression of other protective pathways. The CSCs are further shown to be more resistant to ionizing radiation (IR) and certain chemotherapies and to express high levels of ROS genes.
Genetic Characterization And Prognostic Significance Of Cancer Stem Cells In Cancer
US Patent:
2007022, Sep 20, 2007
Filed:
Oct 31, 2006
Appl. No.:
11/591122
Inventors:
Michael Clarke - Palo Alto CA, US
Xinhao Wang - Fremont CA, US
Robert Cho - San Jose CA, US
Xinhao Wang - Fremont CA, US
Robert Cho - San Jose CA, US
International Classification:
A01K 67/027, C12Q 1/68, G01N 33/574, C12N 5/08
US Classification:
800018000, 435006000, 435325000, 435366000, 435007230
Abstract:
The present invention is related to the identification of cancer stem cells using the MMTV-Wnt-1 transgenic mouse model. These cancer stem cells have a gene expression signature that allows them to be distinguished from their non-tumorigenic counterparts. Moreover, the gene expression pattern can also predict survival in a diverse group of solid tumors.
Compositions And Methods For Treating And Diagnosing Cancer
US Patent:
2008029, Nov 27, 2008
Filed:
May 27, 2008
Appl. No.:
12/127636
Inventors:
Michael F. Clarke - Palo Alto CA, US
Rui Liu - Ann Arbor MI, US
Rui Liu - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 51/00, A61K 39/395, A61P 31/00
US Classification:
424 149, 4241721, 4241361, 4241781
Abstract:
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
Compositions And Methods For Treating And Diagnosing Cancer
US Patent:
2007009, May 3, 2007
Filed:
Jun 13, 2006
Appl. No.:
11/451773
Inventors:
Michael Clarke - Palo Alto CA, US
Xinhao Wang - Fremont CA, US
John Lewicki - Los Gatos CA, US
Austin Gurney - San Francisco CA, US
Xinhao Wang - Fremont CA, US
John Lewicki - Los Gatos CA, US
Austin Gurney - San Francisco CA, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 1/68, G01N 33/574, C12M 3/00
US Classification:
435006000, 435007230, 435287200, 977924000
Abstract:
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer gene signatures useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells.
Compositions And Methods For Treating And Diagnosing Cancer
US Patent:
2007010, May 10, 2007
Filed:
Jun 13, 2006
Appl. No.:
11/451774
Inventors:
Michael Clarke - Palo Alto CA, US
Xinhao Wang - Fremont CA, US
John Lewicki - Los Gatos CA, US
Austin Gurney - San Francisco CA, US
Xinhao Wang - Fremont CA, US
John Lewicki - Los Gatos CA, US
Austin Gurney - San Francisco CA, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 1/68, G01N 33/574, C12N 5/08
US Classification:
435006000, 435007230, 435366000
Abstract:
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.